Public Release:  Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery

RIKEN

IMAGE

IMAGE: The results of the largest international study to date into the genetic basis of rheumatoid arthritis, published in the journal Nature, shed light on the biology of the disease and... view more

Credit: RIKEN

The results of the largest international study to date into the genetic basis of rheumatoid arthritis shed light on the biology of the disease and provide evidence that large-scale genetic studies can assist in the identification of new drugs for complex disorders such as rheumatoid arthritis.

The study, conducted by Dr. Robert M. Plenge from the Harvard Medical School and the Broad Institute in the USA and Dr. Yukinori Okada from the RIKEN Center for Integrative Medical Sciences in Japan, collaborating with colleagues from 70 institutions worldwide, is published today in the journal Nature.

Genome-wide association studies are a method employed by scientists to identify the genes contributing to human disease. The current Nature study is the first to demonstrate that integrating the information provided by genome-wide association studies with existing datasets of genomic and biological information, such as drug targets, can assist in the discovery of drugs to cure human disease.

Rheumatoid arthritis is an autoimmune disease leading to inflammation of the joints and affecting 0.5-1% of adults in the developed world. The disease is thought to be caused by a complex combination of genetic and environmental factors and several genes have been shown to be associated with the disease. However, most of the findings were based on single population studies, and no large-scale trans-ethnic study had been carried out to date.

The international team performed a genome-wide association study meta-analysis on a total of over 100,000 subjects of European and Asian descent - 29,880 rheumatoid arthritis patients and 73,758 controls - by analysing around 10 million genetic variants called single nucleotide polymorphism (SNPs). They identified 42 new regions in the genome (loci) that are associated with rheumatoid arthritis, bringing the total number of known rheumatoid arthritis loci to 101.

By conducting bioinformatics studies integrating existing datasets with this new information, the researchers were able to pinpoint 98 genes in these 101 loci that could potentially contribute to the onset of rheumatoid arthritis. By integrating their findings with existing drug databases they demonstrate that these genes indeed possess many overlapping regions with the genes targeted by approved rheumatoid arthritis drugs - although this wasn't known when the drugs were developed. The team identify existing drugs used to treat cancer that also target rheumatoid arthritis genes and could potentially be used as therapy for the disease, such as CDK4/6 inhibitors.

The bioinformatics study also reveals that there is significant overlap between the genes involved in rheumatoid arthritis, human primary immunodeficiency disorders and blood cancers.

"This study sheds light on the fundamental genes, pathways and cell types that contribute to the onset of rheumatoid arthritis and provides evidence that the genetics of rheumatoid arthritis can provide important information for drug discovery," conclude the authors.

"While there are previous anecdotal examples, our study provides a systematic approach by which human genetic data can be efficiently integrated with other biological information to derive biological insights and drug discovery," they add.

###

For more information please contact:

Juliette Savin
Global Relations Office
RIKEN
Tel: +81-(0)48-462-1225
email: pr@riken.jp

Reference

Okada et al. "Genetics of rheumatoid arthritis contributes to biology and drug discovery" Nature, 2013 DOI: 10.1038/nature12873

About RIKEN

RIKEN is Japan's largest research institute for basic and applied research. Over 2500 papers by RIKEN researchers are published every year in leading scientific and technology journals covering a broad spectrum of disciplines including physics, chemistry, biology, engineering, and medical science. RIKEN's research environment and strong emphasis on interdisciplinary collaboration and globalization has earned a worldwide reputation for scientific excellence. Website: http://www.riken.jp/en Twitter: @riken_en

About the Center for Integrative Medical Sciences

The Center for Integrative Medical Sciences, based in Yokohama, aims to develop revolutionary medical therapies based on collaborative projects between researchers from different areas of science. By achieving a deeper understanding of homeostasis, and how the breakdown of homeostasis leads to disease, scientists at IMS are working to develop personalized preventive medicine and personalized medicine that can allow us to lead healthier lives. The center focuses include genomics, immunology, allergies, inflammation, endocrinology, and the new field of metabolomics. Website: http://www.ims.riken.jp/english/

Acknowledgement of NIH Funding

Research reported in this press release was supported by the Harvard Medical School and the Broad Institute of the National Institutes of Health (NIH) under awards number R01AR056291, R01AR056768, R01AR057108, R01AR059648, R01AR063759, R01AR065944, R21AR056042, U01GM092691, P60AR047785, and K08KAR055688. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.